Skip to main content
. 2022 Sep 23;8(38):eabo6638. doi: 10.1126/sciadv.abo6638

Fig. 1. Illustration of the drug delivery and therapeutic concept.

Fig. 1.

Upon intravenous injection, biomimetic RGD-LNCs follow the route of VLDL. They extravasate from the choriocapillaris, diffuse through the Bruch’s membrane, and accumulate in the RPE. Loaded with antiangiogenic and anti-inflammatory CsA, a simple intravenous injection of the nanotherapeutic has the potential to prevent preterm infants from developing ROP as the therapy counteracts pathologic neovascularization by normalizing VEGF expression and suppresses inflammation.